摘要
目的:通过对重组人p53腺病毒(rAd-p53)瘤内注射联合同步放疗、化疗治疗中晚期鼻咽癌患者的临床观察,探讨其在中晚期鼻咽癌治疗中的增效作用。方法:41例确诊中晚期鼻咽癌的患者随机分为两组。治疗组rAd-p53瘤内注射+同步放化疗,对照组仅行同步放化疗。分别比较两组治疗结束时和治疗后3个月的有效率以及0.5、1、2年的生存率,2年的原发灶复发率、远处转移率和无瘤生存率。同时比较两组治疗过程中主要的药物毒副反应。结果:治疗后3个月,治疗组的完全缓解率优于对照组(P<0.05)。治疗组的无瘤生存率明显高于对照组(P<0.05)。rAd-p53的药物副反应主要是发热。两组骨髓抑制反应的发生率差异无统计学意义(P>0.05)。结论:rAd-p53瘤内注射在中晚期鼻咽癌的同步放化疗中具有增效作用,但其远期疗效仍有待扩大样本量行更长时间的进一步观察。rAd-p53瘤内注射并未增加化疗的毒副反应,具有较大的安全性。
Objective The purpose of our study was to evaluate the synergistic effect of recombinant adenovirus-p53 （rAd-p53） combined with radiotherapy and chemotherapy for patients with advanced nasopharyngeal carcinoma （NPC）. Methods A randomized controlled clinical study on rAd-p53 combined with radiotherapy and chemotherapy in 41 patients with advanced NPC was compared with a control group of 20 advanced NPC patients only treated with radiotherapy and chemotherapy. Patients were monitored for adverse event and side effect. Tumor response was assessed at different time points. Results Complete response rate in the combined treatment group was higher than that of control group （P 〈 0.05）. Disease-free survival rate of the combined treatment group was higher than that of control group （P 〈 0.05）. No dose-limiting toxicity or adverse events appeared, except for transient fever after rAd-p53 administration. Conclusion A potentially synergistic effect of rAd-p53 combined with radiotherapy and chemotherapy was observed in this clinical study. Intratumoral injection of rAd-p53 is safe.
出处
《实用医学杂志》
CAS
北大核心
2011年第13期2341-2344,共4页
The Journal of Practical Medicine
基金
广西壮族自治区卫生厅重点项目(编号:重200721)
关键词
鼻咽肿瘤
RAD-P53
瘤内注射
放疗
化疗
Nasopharyngeal neoplasms
rAd-p53
Intratumoral injection
Radiotherapy
Chemotherapy
